Summary of Key Points Core Viewpoint The Beijing Stock Exchange (BSE) has seen a decrease in trading volume and value over the past week, with a total of 287 listed companies as of December 21, 2025. The market is also witnessing new listings and applications for IPOs, indicating ongoing activity despite the recent declines in trading metrics. Trading Metrics - As of December 21, 2025, the BSE has 287 listed companies with a total share capital of 39.676 billion shares and a circulating share capital of 25.312 billion shares [2] - For the week of December 22-27, 2025, the trading volume was 4.634 billion shares, a decrease of 6.63% week-over-week [3] - The trading value for the same week was 99.934 billion yuan, down 11.68% from the previous week [3] - The average trading price was 21.57 yuan, reflecting a decrease of 5.41% [3] - The BSE 50 Index fell by 1.19% to 1463.04 points, with 28 stocks rising and 22 falling [3] New Listings and IPO Applications - During the week of December 22-27, 2025, one company was listed, and one company opened for subscription [6][12] - A total of 9 companies had their IPO applications accepted, while 4 companies passed the review process [6][38] - As of December 27, 2025, there are 160 companies awaiting review, with 13 accepted, 121 under inquiry, and 14 submitted for registration [6] Recent IPOs - Jiangtian Technology (江天科技) was listed on December 25, 2025, becoming the 287th company on the BSE, with a first-day closing price of 47.85 yuan, up 180.58% from its issue price [8][9] - The company aims to raise 531 million yuan for the construction of a comprehensive R&D and manufacturing base [9] - For the first three quarters of 2025, Jiangtian Technology reported a revenue of 468 million yuan, a year-on-year increase of 10.85%, and a net profit of 89.11 million yuan, up 11.45% [11] Upcoming IPOs - Hengtong Optoelectronics (蘅东光) opened for subscription on December 23, 2025, with a target of raising 323.8 million yuan [13] - The company reported a revenue of 1.315 billion yuan for 2024, a significant increase of 91.38% year-on-year, and a net profit of 224 million yuan, up 123.75% [16] - Other companies, including Miro Technology (觅容科技) and Meiya Technology (美亚科技), have submitted registration applications, aiming to raise 314 million yuan and 200 million yuan, respectively [19][22] Companies Passing Review - Four companies passed the listing committee review during the week, including Ying's Holdings (英氏控股) and Longyuan Co., Ltd. (隆源股份) [24][26] - Ying's Holdings reported revenues of 1.974 billion yuan for 2024, with a net profit of 210 million yuan [25] - Longyuan Co., Ltd. aims to raise 560 million yuan for projects related to new energy systems [28] Companies Completing Counseling - A total of 28 companies completed their counseling work during the week [68] - These companies are preparing for their IPOs, indicating a robust pipeline for future listings on the BSE [68]

Group 1 - The article discusses the approval of four companies for IPOs, with one from the Shenzhen Main Board, one from the ChiNext, and two from the Beijing Stock Exchange [1] - The companies approved include: - Fuen Co., Ltd. focusing on eco-friendly fabric research and sales, projected revenue of 181.28 million and net profit of 25.48 million for 2024 [2] - Sanrui Intelligent Technology Co., Ltd. specializing in drone electric power systems, with projected revenue of 83.15 million and net profit of 32.05 million for 2024 [3] - Xinhengtai New Materials Co., Ltd. focusing on functional polymer foam materials, with projected revenue of 77.42 million and net profit of 8.20 million for 2024 [4] - Puang Medical Technology Co., Ltd. engaged in diabetes care and medical devices, with projected revenue of 31.83 million and net profit of 6.69 million for 2024 [4] Group 2 - Fuen Co., Ltd. has a total of 17.5 million shares before the IPO and is controlled by Paiya Holdings with a 36.57% stake, while the actual controllers hold 83.89% of the shares [5][6] - The company reported revenues of 176.38 million, 151.69 million, 181.28 million, and 93.81 million over the past four years, with net profits of 27.57 million, 22.68 million, 25.48 million, and 10.01 million respectively [7] Group 3 - Sanrui Intelligent Technology Co., Ltd. has a total of 36 million shares before the IPO and is controlled by Wu Min with 81.06% voting rights [13][14] - The company reported revenues of 36.16 million, 53.38 million, 83.15 million, and 43.56 million over the past four years, with net profits of 10.09 million, 16.18 million, 32.05 million, and 15.31 million respectively [15] Group 4 - Xinhengtai New Materials Co., Ltd. has a total of 12.33 million shares before the IPO and is controlled by Chen Chunping and Jin Wei with a combined 75.04% voting rights [21][22] - The company reported revenues of 53.00 million, 67.93 million, 77.42 million, and 38.43 million over the past four years, with net profits of 3.97 million, 9.34 million, 8.20 million, and 4.68 million respectively [23] Group 5 - Puang Medical Technology Co., Ltd. has a total of 4.23 million shares before the IPO and is controlled by Tai You Hong and Pu Mao Partnership with a combined 54.67% stake [27][28] - The company reported revenues of 24.18 million, 23.65 million, 31.83 million, and 17.83 million over the past four years, with net profits of 5.16 million, 4.21 million, 6.69 million, and 4.31 million respectively [30]

Core Viewpoint - Puang Medical Technology Co., Ltd. is preparing for an IPO on the Beijing Stock Exchange, having completed its guidance work with Guojin Securities as the advisory institution [2]. Financial Performance - In 2024, Puang Medical achieved operating revenue of 318.03 million yuan, representing a year-on-year increase of 34.61% [3]. - The net profit for the same period was 64.88 million yuan, up 41.34% compared to the previous year [3]. - The gross profit margin improved to 49.44%, compared to 47.20% in the previous year [3]. Shareholding Structure - The legal representative and chairman, Hu Chaoyu, directly holds 42,079 shares (0.10%) and indirectly controls 28.54% of the voting rights through Taiyouhong, 26.13% through Pumao Partnership, and 4.72% through Hangzhou Youying [4]. - Hu Chaoyu and his spouse, Mao Liuying, collectively control 59.49% of the voting rights, making them the actual controllers of the company [4]. Company Background - Puang Medical was established in January 2013, focusing on the research, production, and sales of diabetes care, general drug infusion, and minimally invasive medical devices [2]. - The registered capital of the company is 42.33 million yuan [2].